NYSEAMERICAN:ASXC Asensus Surgical Q1 2024 Earnings Report $0.35 0.00 (0.00%) As of 08/22/2024 Earnings HistoryForecast Asensus Surgical EPS ResultsActual EPS-$0.07Consensus EPS -$0.05Beat/MissMissed by -$0.02One Year Ago EPSN/AAsensus Surgical Revenue ResultsActual Revenue$1.12 millionExpected Revenue$1.10 millionBeat/MissBeat by +$20.00 thousandYoY Revenue GrowthN/AAsensus Surgical Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call DateTuesday, May 14, 2024Conference Call Time4:30PM ETConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Asensus Surgical Q1 2024 Earnings Call TranscriptProvided by QuartrMay 14, 2024 ShareLink copied to clipboard.There are 7 speakers on the call. Operator00:00:00Good afternoon, ladies and gentlemen, and welcome to the Ascensus Surgical First Quarter Financial and Operating Results Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Tuesday, May 14, 2024. I would now like to turn the conference over to Mark Klausner from Westwicke Partners. Operator00:00:28Please go ahead. Speaker 100:00:30Good afternoon, everyone, and thank you for joining us for the Ascentis Surgical First Quarter Business and Financial Update Conference Call. On the call with me today are Anthony Fernando, President and Chief Executive Officer and Shamiz Rampertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward looking statements provided under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward looking statements due to risks and uncertainties associated with the company's business, including any geopolitical factors beyond our control and the uncertainty of whether a definitive merger agreement can be successfully negotiated with Carl Storz and if executed will be approved by our stockholders. The company undertakes no obligation to update the information provided on this call. Speaker 100:01:29For a discussion of risks and uncertainties associated with the Ascensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2023 Form 10 ks filed in March 2024 and the Form 10 Q expected to be filed later today and any other filings we make with the SEC. During this call, we will also present certain non GAAP information related to adjusted net loss attributable to common stockholders and the adjusted net loss per share attributable to common stockholders. Management believes that these non GAAP financial measures taken in conjunction with U. S. GAAP Financial Measures provide useful information for both management and investors by excluding certain non cash and other expenses that are not indicative of the company's core operating results. Speaker 100:02:20Management uses non GAAP financial measures to compare our performance relative to forecast and strategic plans, to benchmark our performance externally against competitors and for certain compensation decisions. Reconciliations from U. S. GAAP to non GAAP results are presented in the tables accompanying our earnings release, which can be found in the Investor Relations section of our website. With that, it's my pleasure to turn the call over to Ascensus Surgical's President and Chief Executive Officer, Anthony Fernando. Speaker 200:02:49Thanks, Mark, and thank you all for joining with us today. To start, I'll give a summary of our recent performance and notable accomplishments in the Q1 of 2024. Then Shamish will dive into our financial results. Following that, I'll discuss what lies ahead of us in 2024. And finally, we'll open the floor for any questions you may have. Speaker 200:03:14First, I'd like to provide an update on a recent development for the company. In early April, we entered into a nonbinding letter of intent with Carl Storz regarding a potential acquisition of Athensus. Under the proposed terms, Carl Storz would acquire 100 percent of our outstanding common stock for $0.35 per share in cash. As a reminder, Carl Storz is a global leader in the medical technology industry, offering state of the art endoscopes, medical instruments and devices for minimally invasive procedures across various surgical specialties. Carlsdorf is an independent family owned company with a strong global presence and is committed to visionary design, precision craftsmanship and clinical effectiveness. Speaker 200:04:08We believe that this potential acquisition by Karl Storz provides an attractive opportunity to deliver unmatched clinical value coupled with state of the art robotics and digital solutions to the operating growth. CalSTOR's global presence and scale, resources and commercial capabilities could enable broader adoption of our combined digital surgery solutions and maximize the potential of Luna and the ISU. As previously disclosed, we have granted Carl Storz a 10 week exclusivity period to conduct due diligence and negotiate a definitive merger agreement. This exclusivity period started on March 28, 2024 and is ongoing. During the exclusivity period, Karl Storz is providing us with up to $10,000,000 in financing through a fully secured promissory note to support our operations. Speaker 200:05:13And if a definitive merger agreement is successfully negotiated and executed, an additional $10,000,000 will be available to us as we pursue all necessary approvals. Since announcing the potential transaction on April 3, we have been working closely with Carl Storz to facilitate the due diligence process. As of today, we have drawn the first $7,000,000 of the 10,000,000 dollars tranche of the note, which has provided liquidity for operations. To evaluate the potential terms of the transaction and make a recommendation to stockholders, our Board has formed a transaction committee. While there is no assurance a transaction will be completed, we believe exploring this opportunity with Karl Storz is in the best interest of the company and our stockholders. Speaker 200:06:12If we are able to finalize the definitive merger agreement with Karl Storz, we will move expeditiously to secure stockholder approval for the proposed acquisition. Further updates will be provided as appropriate. Despite the ongoing diligence activities, we remain focused on our business and in particular, the continued growth of the Senhance system and ongoing development of the Luna system and ISU. In the Q1, the Senhance system was used in nearly 900 procedures worldwide. By continually capturing data from these surgeries, our machine learning capabilities improve, allowing us to provide increasingly valuable clinical insights to surgeons through the intelligent surgical unit in the future. Speaker 200:07:02With specialized 3 millimeter and 5 millimeter instruments, the Senhance surgical system is uniquely designed for the delicate nature of pediatric procedures. As more pediatric surgeons recognize Assensors' unique system design, which not only preserves minimally invasive surgery, but also advances laparoscopy and robotics with digital surgery solutions, we expect the number of pediatric procedures performed using Senhance and the ISU to continue to grow. Moving to new program initiations. In April, we announced that Sendai Tokushukai Hospital in Japan entered into an agreement to lease and utilize 1 of our Senhance surgical systems. This represents the 2nd institution within 1 of Japan's largest private hospital systems to adopt our technology. Speaker 200:08:00I view this as further validation of the growing trust in our Senhance system in the Japanese market. In summary, the Q1 saw steady growth in the adoption of our digital surgery solutions and continued progress in enhancing the capabilities of the Senhance platform. We are excited about the potential opportunity to join forces with Carl Storz to accelerate our mission of digitizing the surgical environment. While we work towards a potential transaction, our team remains focused on executing against our key initiatives, including driving further adoption through new program initiations, increasing procedure volumes, expanding our clinical registry and advancing our Luna platform development. We believe we are well positioned for continued momentum in 2024. Speaker 200:08:59With that, I would like to turn the call over to Sameer for a financial update. Speaker 300:09:04Thanks, Anthony. Turning to the Q1. For the 3 months ended March 31, 2024, the company reported revenue of $1,100,000 as compared to revenue of $1,000,000 in the 3 months ended March 31, 2023. Revenue in the Q1 of 2024 included $500,000 in lease revenue, dollars 300,000 in instruments and accessories, and $300,000 in services. For the 3 months ended March 31, 2024, total operating expenses were $22,700,000 as compared to 20.4 dollars in the 3 months ended March 31, 2023. Speaker 300:09:49For the 3 months ended March 31, 2024, net loss attributable to common stockholders was $22,500,000 or $0.08 per share, as compared to a net loss attributable to common stockholders of $22,200,000 or $0.09 per share in the 3 months ended March 31, 2023. For the 3 months ended March 31, 2024, the adjusted net loss attributable to common stockholders was $18,000,000 or $0.07 per share as compared to an adjusted net loss of $22,000,000 or $0.09 per share in the 3 months ended March 31, 2023. Adjusted net loss is GAAP net loss adjusted for the following items, amortization of intangible assets, change in fair value of contingent consideration and change in fair value of warrant liabilities, all of which are non cash charges. Adjusted net loss attributable to common stockholders is a non GAAP financial measure. Reconciliation from GAAP to non GAAP measures can be found in our earnings release. Speaker 300:10:59Turning to the balance sheet. The company had cash, cash equivalents and short term investments, excluding restricted cash of approximately $8,000,000 as of March 31, 2024. Based on the recent financing received from Carl Storz and our current operating plan, we project that available cash will now sustain operations into Q3 20 24. If we signed the definitive review with Carl Storz, the additional $10,000,000 that we would be eligible to receive would support operations into Q4 2024 if we secure such financing. I'll turn the call back over to Anthony. Speaker 200:11:40Thanks, Amit. Our key initiatives for 2024 center around advancing the development of our next generation Luna Surgical System and associated digital solutions, while continuing to drive adoption of our current Senhance platform. Luna, we plan to freeze the system design in Q3, conduct verification and validation testing in Q4 and initiate pilot manufacturing to prepare for regulatory submissions. We continue to anticipate Luna's 510 submission in the second half of twenty twenty five, clearance in the first half of twenty twenty six and then launch following clearance. In parallel, our digital roadmap includes integrating advanced analytical tools, innovative training and communication capabilities and enhanced safety features into the Luna Digital Ecosystem. Speaker 200:12:41On the ISU hardware front, we are ramping up manufacturing with partners for the Future Intelligent Surgical Unit or ISU configurations aiming to complete designs for both the integrated Luna ISU and the standalone ISU by mid year 2024. For our current Senhance system, we continue to expect to initiate 8 to 10 new programs globally in 2024 and anticipate 15% to 20% annual procedure volume growth. 2024 will be a pivotal year as we prepare to bring our Luna platform and advanced digital capabilities to market, while sustaining growth with Senhance adoption worldwide. We have a set of strategic milestones to accomplish this year, keeping us firmly on track towards our vision. With that, we would now like to open the line for questions. Operator00:13:46Thank you. Ladies and gentlemen, we will now conduct the question and answer Your first question comes from the line of Swayampakula Ramakanth from H. C. Wainwright. Your line is now open. Speaker 400:14:26Thank you. Good afternoon, Anthony and Shamish. So I know you can't talk too much about your discussions with call stores. However, I just would like to understand a little bit of the timeline. So when exactly did the 10 week period exclusivity period start? Speaker 400:14:54When would it end? And what needs to happen for them to sign a letter to actually go through the transaction and acquire you? Speaker 200:15:14Hi, RK. Thanks for your question. So as you said, we continue to collaboratively work with Carl Storz. We are currently 7 weeks into the 10 week exclusivity period and the exclusivity period began on March 28. So as you said, we can't comment further, but the work is going on and the diligence is ongoing and that's kind of where we are currently. Speaker 400:15:52So I mean obviously we are wishing for the best for the shareholders and the company. However, playing the devil's advocate. If something happens such a way that they are not going to go through this transaction, then what's the process? Does that mean this $10,000,000 that you got becomes a promissory note and you go on with your business in terms of generating funds and maintaining operations or I'm just trying to put a what if scenario here. Speaker 200:16:42That's correct, RK. It's a secured promissory note, and we would be able to continue operations as we would have otherwise. Speaker 400:16:55Okay. So in terms of operations itself, normally when some transactions like this are in progress or obviously you had to come out and publicly talk about it, which is kind of unique. In situations like this, are you in the field, are you sensing anything at all in terms of people being a little bit hesitant to go through transactions that they might have started? And how is it really affecting your operations? Speaker 200:17:41I mean, not sure exactly. I'll try to answer the question. I mean typically any transaction one goes through diligence before entering into a definitive agreement. And in our scenario, we announced the LOI on April 3, primarily because of the promissory note. So otherwise, the process that's ongoing would have taken place without any public knowledge. Speaker 400:18:15Correct. Speaker 200:18:15But right now, that's the reason why we disclosed what we had to. And then as soon as we are now before the 10 week mark, that's when we'll be able to talk and give more details along with the definitive agreement. Speaker 400:18:34No, no. My question was on the commercial front, are you seeing anything any hesitancy or things are happening as they would normally happen in terms of placements? And so those are the things that I'm asking about. Speaker 200:18:53Okay. Sorry, Aakir, I misunderstood the question. Currently, it's ongoing and we have not seen any challenges. I think Carlsdott is a very well known company among all of our existing and potential future customers. So we have not had any challenges there. Speaker 200:19:20I think it's perceived as positive news in the field and we continue to execute on the pipeline globally. Speaker 400:19:31Thank you. Thanks for taking all my questions. Speaker 200:19:34Thank you, RK. Operator00:19:39Your next question comes from the line of Ross Osborne from Cantor Fitzgerald. Your line is now open. Speaker 500:19:47Hi, guys. This is Matt on for Ross. Thanks for taking the question. I just want to start off by asking about your Senhance initiation in Japan this past April. Now that you've placed a couple of systems in Japan, what trends are you guys seeing in terms of adoption and growth in the region? Speaker 200:20:04Thanks, Matt. Thanks for your question. Japan, it's one of our faster growing markets next to Europe and primarily this site focused on pediatrics and there are several other sites. So we've seen very good positive momentum in Japan in terms of case volume growth and also system placements. And hopefully, the pipeline also looks pretty good for the rest of the year so that we can deliver on the 8 to 10 systems for the full year. Speaker 200:20:45But Japan has been a growth driver for us in terms of placements and also case volume. Speaker 500:20:54Got it. That's helpful. Just switching gears a bit, I wanted to ask if you guys can provide any insight into how Cross Storage plans to utilize your assets in terms of maybe just integrating the ISU versus continuing the development of Luna? Speaker 200:21:09Yes, Matt. Unfortunately, I can't get into any of the details because currently it's just purely a diligence process and those kinds of plans of integration that will come next but not at this time. Speaker 600:21:27Got it. Sounds good. And then Speaker 500:21:29I guess just one more follow-up from me. I was wondering if you guys can provide any insights into the timeline and how the potential acquisition and integration may impact your previously guided timeline for LUNO? Speaker 200:21:45I mean, currently from a time line point of view, we are moving ahead as we've disclosed and shared with all of you on our time line. So the Luna program is making extremely good progress and everything is on track. And I don't we are not anticipating any timeline shifts because of this transaction at all. Speaker 600:22:15Got it. Sounds good. Thanks for Speaker 500:22:16the color. Thanks for taking the questions, guys. Thank you, Matt. There are Operator00:22:22no further questions at this time. I will now turn the call back to Mr. Anthony Fernando. Please continue. Speaker 200:22:30Thank you, operator. Thank you everyone for joining today's call and we look forward to updating you on our progress throughout the year. Operator00:22:41Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallAsensus Surgical Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Asensus Surgical Earnings HeadlinesAsensus Surgical Announces Closing of Acquisition by KARL STORZAugust 22, 2024 | globenewswire.comDurham public company staves off potential bankruptcy, will be acquiredAugust 21, 2024 | bizjournals.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 25, 2025 | Premier Gold Co (Ad)Durham company could face bankruptcy if $95M sale failsAugust 15, 2024 | bizjournals.comBiggest stock movers today: NU, K, and moreAugust 14, 2024 | msn.comAsensus says it expects to file for bankruptcy if merger vote failsAugust 13, 2024 | msn.comSee More Asensus Surgical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Asensus Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Asensus Surgical and other key companies, straight to your email. Email Address About Asensus SurgicalAsensus Surgical (NYSEAMERICAN:ASXC), a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.View Asensus Surgical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 7 speakers on the call. Operator00:00:00Good afternoon, ladies and gentlemen, and welcome to the Ascensus Surgical First Quarter Financial and Operating Results Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Tuesday, May 14, 2024. I would now like to turn the conference over to Mark Klausner from Westwicke Partners. Operator00:00:28Please go ahead. Speaker 100:00:30Good afternoon, everyone, and thank you for joining us for the Ascentis Surgical First Quarter Business and Financial Update Conference Call. On the call with me today are Anthony Fernando, President and Chief Executive Officer and Shamiz Rampertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward looking statements provided under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward looking statements due to risks and uncertainties associated with the company's business, including any geopolitical factors beyond our control and the uncertainty of whether a definitive merger agreement can be successfully negotiated with Carl Storz and if executed will be approved by our stockholders. The company undertakes no obligation to update the information provided on this call. Speaker 100:01:29For a discussion of risks and uncertainties associated with the Ascensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2023 Form 10 ks filed in March 2024 and the Form 10 Q expected to be filed later today and any other filings we make with the SEC. During this call, we will also present certain non GAAP information related to adjusted net loss attributable to common stockholders and the adjusted net loss per share attributable to common stockholders. Management believes that these non GAAP financial measures taken in conjunction with U. S. GAAP Financial Measures provide useful information for both management and investors by excluding certain non cash and other expenses that are not indicative of the company's core operating results. Speaker 100:02:20Management uses non GAAP financial measures to compare our performance relative to forecast and strategic plans, to benchmark our performance externally against competitors and for certain compensation decisions. Reconciliations from U. S. GAAP to non GAAP results are presented in the tables accompanying our earnings release, which can be found in the Investor Relations section of our website. With that, it's my pleasure to turn the call over to Ascensus Surgical's President and Chief Executive Officer, Anthony Fernando. Speaker 200:02:49Thanks, Mark, and thank you all for joining with us today. To start, I'll give a summary of our recent performance and notable accomplishments in the Q1 of 2024. Then Shamish will dive into our financial results. Following that, I'll discuss what lies ahead of us in 2024. And finally, we'll open the floor for any questions you may have. Speaker 200:03:14First, I'd like to provide an update on a recent development for the company. In early April, we entered into a nonbinding letter of intent with Carl Storz regarding a potential acquisition of Athensus. Under the proposed terms, Carl Storz would acquire 100 percent of our outstanding common stock for $0.35 per share in cash. As a reminder, Carl Storz is a global leader in the medical technology industry, offering state of the art endoscopes, medical instruments and devices for minimally invasive procedures across various surgical specialties. Carlsdorf is an independent family owned company with a strong global presence and is committed to visionary design, precision craftsmanship and clinical effectiveness. Speaker 200:04:08We believe that this potential acquisition by Karl Storz provides an attractive opportunity to deliver unmatched clinical value coupled with state of the art robotics and digital solutions to the operating growth. CalSTOR's global presence and scale, resources and commercial capabilities could enable broader adoption of our combined digital surgery solutions and maximize the potential of Luna and the ISU. As previously disclosed, we have granted Carl Storz a 10 week exclusivity period to conduct due diligence and negotiate a definitive merger agreement. This exclusivity period started on March 28, 2024 and is ongoing. During the exclusivity period, Karl Storz is providing us with up to $10,000,000 in financing through a fully secured promissory note to support our operations. Speaker 200:05:13And if a definitive merger agreement is successfully negotiated and executed, an additional $10,000,000 will be available to us as we pursue all necessary approvals. Since announcing the potential transaction on April 3, we have been working closely with Carl Storz to facilitate the due diligence process. As of today, we have drawn the first $7,000,000 of the 10,000,000 dollars tranche of the note, which has provided liquidity for operations. To evaluate the potential terms of the transaction and make a recommendation to stockholders, our Board has formed a transaction committee. While there is no assurance a transaction will be completed, we believe exploring this opportunity with Karl Storz is in the best interest of the company and our stockholders. Speaker 200:06:12If we are able to finalize the definitive merger agreement with Karl Storz, we will move expeditiously to secure stockholder approval for the proposed acquisition. Further updates will be provided as appropriate. Despite the ongoing diligence activities, we remain focused on our business and in particular, the continued growth of the Senhance system and ongoing development of the Luna system and ISU. In the Q1, the Senhance system was used in nearly 900 procedures worldwide. By continually capturing data from these surgeries, our machine learning capabilities improve, allowing us to provide increasingly valuable clinical insights to surgeons through the intelligent surgical unit in the future. Speaker 200:07:02With specialized 3 millimeter and 5 millimeter instruments, the Senhance surgical system is uniquely designed for the delicate nature of pediatric procedures. As more pediatric surgeons recognize Assensors' unique system design, which not only preserves minimally invasive surgery, but also advances laparoscopy and robotics with digital surgery solutions, we expect the number of pediatric procedures performed using Senhance and the ISU to continue to grow. Moving to new program initiations. In April, we announced that Sendai Tokushukai Hospital in Japan entered into an agreement to lease and utilize 1 of our Senhance surgical systems. This represents the 2nd institution within 1 of Japan's largest private hospital systems to adopt our technology. Speaker 200:08:00I view this as further validation of the growing trust in our Senhance system in the Japanese market. In summary, the Q1 saw steady growth in the adoption of our digital surgery solutions and continued progress in enhancing the capabilities of the Senhance platform. We are excited about the potential opportunity to join forces with Carl Storz to accelerate our mission of digitizing the surgical environment. While we work towards a potential transaction, our team remains focused on executing against our key initiatives, including driving further adoption through new program initiations, increasing procedure volumes, expanding our clinical registry and advancing our Luna platform development. We believe we are well positioned for continued momentum in 2024. Speaker 200:08:59With that, I would like to turn the call over to Sameer for a financial update. Speaker 300:09:04Thanks, Anthony. Turning to the Q1. For the 3 months ended March 31, 2024, the company reported revenue of $1,100,000 as compared to revenue of $1,000,000 in the 3 months ended March 31, 2023. Revenue in the Q1 of 2024 included $500,000 in lease revenue, dollars 300,000 in instruments and accessories, and $300,000 in services. For the 3 months ended March 31, 2024, total operating expenses were $22,700,000 as compared to 20.4 dollars in the 3 months ended March 31, 2023. Speaker 300:09:49For the 3 months ended March 31, 2024, net loss attributable to common stockholders was $22,500,000 or $0.08 per share, as compared to a net loss attributable to common stockholders of $22,200,000 or $0.09 per share in the 3 months ended March 31, 2023. For the 3 months ended March 31, 2024, the adjusted net loss attributable to common stockholders was $18,000,000 or $0.07 per share as compared to an adjusted net loss of $22,000,000 or $0.09 per share in the 3 months ended March 31, 2023. Adjusted net loss is GAAP net loss adjusted for the following items, amortization of intangible assets, change in fair value of contingent consideration and change in fair value of warrant liabilities, all of which are non cash charges. Adjusted net loss attributable to common stockholders is a non GAAP financial measure. Reconciliation from GAAP to non GAAP measures can be found in our earnings release. Speaker 300:10:59Turning to the balance sheet. The company had cash, cash equivalents and short term investments, excluding restricted cash of approximately $8,000,000 as of March 31, 2024. Based on the recent financing received from Carl Storz and our current operating plan, we project that available cash will now sustain operations into Q3 20 24. If we signed the definitive review with Carl Storz, the additional $10,000,000 that we would be eligible to receive would support operations into Q4 2024 if we secure such financing. I'll turn the call back over to Anthony. Speaker 200:11:40Thanks, Amit. Our key initiatives for 2024 center around advancing the development of our next generation Luna Surgical System and associated digital solutions, while continuing to drive adoption of our current Senhance platform. Luna, we plan to freeze the system design in Q3, conduct verification and validation testing in Q4 and initiate pilot manufacturing to prepare for regulatory submissions. We continue to anticipate Luna's 510 submission in the second half of twenty twenty five, clearance in the first half of twenty twenty six and then launch following clearance. In parallel, our digital roadmap includes integrating advanced analytical tools, innovative training and communication capabilities and enhanced safety features into the Luna Digital Ecosystem. Speaker 200:12:41On the ISU hardware front, we are ramping up manufacturing with partners for the Future Intelligent Surgical Unit or ISU configurations aiming to complete designs for both the integrated Luna ISU and the standalone ISU by mid year 2024. For our current Senhance system, we continue to expect to initiate 8 to 10 new programs globally in 2024 and anticipate 15% to 20% annual procedure volume growth. 2024 will be a pivotal year as we prepare to bring our Luna platform and advanced digital capabilities to market, while sustaining growth with Senhance adoption worldwide. We have a set of strategic milestones to accomplish this year, keeping us firmly on track towards our vision. With that, we would now like to open the line for questions. Operator00:13:46Thank you. Ladies and gentlemen, we will now conduct the question and answer Your first question comes from the line of Swayampakula Ramakanth from H. C. Wainwright. Your line is now open. Speaker 400:14:26Thank you. Good afternoon, Anthony and Shamish. So I know you can't talk too much about your discussions with call stores. However, I just would like to understand a little bit of the timeline. So when exactly did the 10 week period exclusivity period start? Speaker 400:14:54When would it end? And what needs to happen for them to sign a letter to actually go through the transaction and acquire you? Speaker 200:15:14Hi, RK. Thanks for your question. So as you said, we continue to collaboratively work with Carl Storz. We are currently 7 weeks into the 10 week exclusivity period and the exclusivity period began on March 28. So as you said, we can't comment further, but the work is going on and the diligence is ongoing and that's kind of where we are currently. Speaker 400:15:52So I mean obviously we are wishing for the best for the shareholders and the company. However, playing the devil's advocate. If something happens such a way that they are not going to go through this transaction, then what's the process? Does that mean this $10,000,000 that you got becomes a promissory note and you go on with your business in terms of generating funds and maintaining operations or I'm just trying to put a what if scenario here. Speaker 200:16:42That's correct, RK. It's a secured promissory note, and we would be able to continue operations as we would have otherwise. Speaker 400:16:55Okay. So in terms of operations itself, normally when some transactions like this are in progress or obviously you had to come out and publicly talk about it, which is kind of unique. In situations like this, are you in the field, are you sensing anything at all in terms of people being a little bit hesitant to go through transactions that they might have started? And how is it really affecting your operations? Speaker 200:17:41I mean, not sure exactly. I'll try to answer the question. I mean typically any transaction one goes through diligence before entering into a definitive agreement. And in our scenario, we announced the LOI on April 3, primarily because of the promissory note. So otherwise, the process that's ongoing would have taken place without any public knowledge. Speaker 400:18:15Correct. Speaker 200:18:15But right now, that's the reason why we disclosed what we had to. And then as soon as we are now before the 10 week mark, that's when we'll be able to talk and give more details along with the definitive agreement. Speaker 400:18:34No, no. My question was on the commercial front, are you seeing anything any hesitancy or things are happening as they would normally happen in terms of placements? And so those are the things that I'm asking about. Speaker 200:18:53Okay. Sorry, Aakir, I misunderstood the question. Currently, it's ongoing and we have not seen any challenges. I think Carlsdott is a very well known company among all of our existing and potential future customers. So we have not had any challenges there. Speaker 200:19:20I think it's perceived as positive news in the field and we continue to execute on the pipeline globally. Speaker 400:19:31Thank you. Thanks for taking all my questions. Speaker 200:19:34Thank you, RK. Operator00:19:39Your next question comes from the line of Ross Osborne from Cantor Fitzgerald. Your line is now open. Speaker 500:19:47Hi, guys. This is Matt on for Ross. Thanks for taking the question. I just want to start off by asking about your Senhance initiation in Japan this past April. Now that you've placed a couple of systems in Japan, what trends are you guys seeing in terms of adoption and growth in the region? Speaker 200:20:04Thanks, Matt. Thanks for your question. Japan, it's one of our faster growing markets next to Europe and primarily this site focused on pediatrics and there are several other sites. So we've seen very good positive momentum in Japan in terms of case volume growth and also system placements. And hopefully, the pipeline also looks pretty good for the rest of the year so that we can deliver on the 8 to 10 systems for the full year. Speaker 200:20:45But Japan has been a growth driver for us in terms of placements and also case volume. Speaker 500:20:54Got it. That's helpful. Just switching gears a bit, I wanted to ask if you guys can provide any insight into how Cross Storage plans to utilize your assets in terms of maybe just integrating the ISU versus continuing the development of Luna? Speaker 200:21:09Yes, Matt. Unfortunately, I can't get into any of the details because currently it's just purely a diligence process and those kinds of plans of integration that will come next but not at this time. Speaker 600:21:27Got it. Sounds good. And then Speaker 500:21:29I guess just one more follow-up from me. I was wondering if you guys can provide any insights into the timeline and how the potential acquisition and integration may impact your previously guided timeline for LUNO? Speaker 200:21:45I mean, currently from a time line point of view, we are moving ahead as we've disclosed and shared with all of you on our time line. So the Luna program is making extremely good progress and everything is on track. And I don't we are not anticipating any timeline shifts because of this transaction at all. Speaker 600:22:15Got it. Sounds good. Thanks for Speaker 500:22:16the color. Thanks for taking the questions, guys. Thank you, Matt. There are Operator00:22:22no further questions at this time. I will now turn the call back to Mr. Anthony Fernando. Please continue. Speaker 200:22:30Thank you, operator. Thank you everyone for joining today's call and we look forward to updating you on our progress throughout the year. Operator00:22:41Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.Read morePowered by